On Jan. 22, 2018, Celgene and Juno Therapeutics announced the signing of a merger agreement in which Celgene acquired Juno for $87 per share in cash, or a total of $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene (approximately 9.7% of outstanding shares).

Celgene planned to expand its existing center of excellence for immuno-oncology translational medicine by leveraging Juno’s research and development facility in Seattle, WA as well as Juno’s manufacturing facility in Bothell, WA.